

Dear Sir,

RE PRADAXA

I strongly urge you to reconsider your decision to stall the full release of PRADAXA

Rarely in my medical lifetime has there been release of a safe class of drug that is so obviously cost effective.

In the prophylactic management of thromboembolism in patients with atrial fibrillation. PRADAXA is that!

PRADAXA has the advantage of simplicity in a population that are often aged.

It is cost effective in that anticoagulation clinics ,frequent visits to Drs. and pathologists for INRs are avoided.

Risk of bleeding or clotting complications around surgical procedures will be reduced due to short half-life.

After costs of stroke events will be reduced.

PRADAXA's release is a 'no brainer'as far as I am concerned as a clinician, and I believe it was a most unwise decision to stall it's release, and I hope you will reverse that decision in the interests of patient care.

Your sincerely

DR Ian Bailey MB BS Hons1 FRACP FACC OAM